VU6081679'un Keşfi, Parkinson Hastalığının Preklinik Bir Modelinde Metabotropik Glutamat Reseptörü 8'in Yeni Bir Pozitif Allosterik Modülatörü.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

Herein, we report a potent, CNS penetrant, orally bioavailable metabotropic glutamate receptor subtype 8 (mGlu8) positive allosteric modulator (PAM), VU6081679, that shows robust efficacy in a rodent model of Parkinson's disease. A high-throughput screening effort and subsequent structure-activity relationship study led to the discovery of VU6081679, an mGlu8-preferring PAM with good potency at rat, mouse, and human mGlu8. Molecular docking into a published cryo-EM structure supports binding in an allosteric pocket at the extracellular TM6/TM7 dimer interface. VU6081679 displays a favorable rodent DMPK profile and demonstrates robust efficacy in a haloperidol-induced catalepsy model of Parkinson's disease in both rats and mice. Additional studies conducted in mGlu8 knockout mice confirmed that the observed efficacy is mGlu8-mediated.

İlgili konular